Evelo Biosciences, Inc. (EVLO)
Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational oral biologic based on extracellular vesicles targeting inflammatory diseases; and EDP1908, a drug candidate focused on cancer. Established in 2014, Evelo Biosciences, Inc. operates from its headquarters in Cambridge, Massachusetts.
Sector: Biotechnology
Industry: Biotechnology
Evelo Biosciences, Inc.
- 1:20Reverse splitJun 30, 202320 shares → 1
- 1:100Reverse splitJun 29, 2006100 shares → 1
| Period | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | - | - | - | - | - | - | - |
| Research and Development | $78.55M | $83.64M | $69.62M | $63.13M | $39.88M | $19.96M | $9.13M |
| Selling, General, and Administrative | $29.91M | $31.75M | $22.27M | $23.23M | $18.22M | $7.57M | $3.89M |
| Other | $0 | $0 | $0 | $0 | $0 | $0 | -$20K |
| Total Operating Expenses | $108.47M | $115.4M | $91.89M | $86.36M | $58.1M | $27.53M | $13.03M |
| Operating Income (EBIT) | -$108.47M | -$115.4M | -$91.89M | -$86.36M | -$58.1M | -$27.53M | -$13.03M |
| Operating Margin | - | - | - | - | - | - | - |
| Interest Expense | $4.67M | $3.61M | $2.11M | $1.05M | $1.56M | $0 | $0 |
| Interest Income | $5K | $4K | $0 | $1K | $0 | $0 | $0 |
| Other Income (Expense) | -$5.13M | -$6.35M | -$1.37M | $885K | $1.16M | -$516K | -$307K |
| Income Before Tax (EBT) | -$113.6M | -$121.75M | -$93.26M | -$85.47M | -$56.95M | -$28.05M | -$13.33M |
| Income Tax Expense | $930K | $428K | $409K | $190K | -$3.09M | $215K | $0 |
| Net Income | -$114.53M | -$122.18M | -$93.67M | -$85.66M | -$53.85M | -$28.05M | -$13.33M |
| Net Income Margin | - | - | - | - | - | - | - |
| Supplementary Data | |||||||
| EPS | -26.28 | -46.18 | -47.45 | -53.49 | -49.25 | -149.98 | -94.55 |
| Diluted EPS | -26.28 | -46.18 | -47.45 | -53.49 | -49.25 | -149.55 | -94.06 |
| Weighted Average OS | 4.36M | 2.65M | 1.97M | 1.60M | 1.09M | 187,000 | 141,000 |
| EBITDA | -$106.34M | -$115.4M | -$89.86M | -$82.66M | -$53.45M | $834K | $495K |
| EBITDA Margin | - | - | - | - | - | - | - |
| Period | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $47.94M | $68.44M | $68.86M | $77.83M | $147.92M | $38.25M | $15.54M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $47.94M | $68.44M | $68.86M | $77.83M | $147.92M | $38.25M | $15.54M |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $3.63M | $0 | $250K | -$3.18M | $0 | $0 | $0 |
| Total Current Assets | $51.57M | $71.03M | $70.98M | $77.83M | $147.92M | $38.78M | $15.72M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $11.71M | $15.53M | $18.23M | $8.34M | $6.92M | $3.5M | $2.5M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $1.16M | $1.31M | $3.55M | $4.75M | $5.02M | $1.51M | $346K |
| Total Long-Term Assets | $12.87M | $16.84M | $21.78M | $13.09M | $11.95M | $5.01M | $2.85M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $64.44M | $87.87M | $90.64M | $90.92M | $159.87M | $43.79M | $18.57M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $1.76M | $1.6M | $1.44M | $620K | $1.52M | $1.41M | $637K |
| Short-Term Debt | $0 | $1.95M | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $13.07M | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $1.62M | $742K | $7.76M | $9.12M | $7.72M | $2.43M | $300K |
| Total Current Liabilities | $12.39M | $17.36M | $19.83M | $9.74M | $9.23M | $3.84M | $2.25M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $43.61M | $46.56M | $30.05M | $19.63M | $12.3M | $9.97M | $9.93M |
| Long-Term Unearned Revenue | $7.5M | $7.5M | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $659K | $7.5M | $284K | $1.35M | $1.38M | $580K | $865K |
| Total Long-Term Liabilities | $57.04M | $61.84M | $40.32M | $20.98M | $13.68M | $10.55M | $10.8M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $69.43M | $79.2M | $60.15M | $30.72M | $22.92M | $14.38M | $13.04M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $90.92M | $0 | $84K | $33.86M |
| Common Stock | $111K | $54K | $47K | $32K | $32K | $20K | $4K |
| Retained Earnings | -$529.22M | -$414.69M | -$292.52M | -$198.85M | -$113.38M | -$56.41M | -$28.34M |
| Comprehensive Income & Other | $0 | $0 | $0 | -$90.92M | -$18K | -$1.43M | -$595K |
| Other Stockholders' Equity | $524.12M | $423.31M | $322.96M | $259.02M | $250.3M | $85.79M | $33.86M |
| Total Equity | -$4.99M | $8.67M | $30.48M | $60.2M | $136.95M | $29.4M | $5.53M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $64.44M | $87.87M | $90.64M | $90.92M | $159.87M | $43.79M | $18.57M |
| Supplementary Data | |||||||
| Total Debt | $51.14M | $56.29M | $40.04M | $19.63M | $12.3M | $9.97M | $9.93M |
| Net Debt | $3.2M | -$12.15M | -$28.82M | -$58.2M | -$135.61M | -$28.28M | -$5.61M |
| Period | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
| Operating Activities | |||||||
| Net Income | -$114.53M | -$122.18M | -$93.67M | -$85.47M | -$56.95M | -$28.05M | -$13.33M |
| Depreciation & Amortization | $2.06M | $2.22M | $2.03M | $1.76M | $1.94M | $834K | $495K |
| Deferred Income Tax | $0 | $3.22M | -$6K | -$166K | $406K | $301K | $20K |
| Stock-Based Compensation | $15.16M | $15.85M | $8.47M | $8.16M | $6.06M | $1.54M | $419K |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $170K | $159K | $837K | -$585K | -$221K | $774K | -$43K |
| Other Working Capital | -$9.84M | $1.91M | $6.93M | $4.06M | $1.39M | $1.3M | $99K |
| Total Working Capital Change | -$9.67M | $2.07M | $7.76M | $3.47M | $1.16M | $2.07M | $56K |
| Other Non-Cash Items | $5.74M | $2.1M | $2.35M | $255K | $103K | $35K | $28K |
| Net Cash from Operating | -$101.23M | -$96.72M | -$73.06M | -$71.98M | -$47.28M | -$23.27M | -$12.31M |
| Investing Activities | |||||||
| Capital Expenditures | -$622K | -$1.52M | -$1.32M | -$3.03M | -$5.46M | -$1.74M | -$1.25M |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $10.49M |
| Purchases of Investments | $0 | $0 | $0 | $0 | -$136.09M | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $55M | $81.25M | $0 | $0 |
| Other Investing Activities | $0 | $38K | $6K | $2K | $171K | $0 | $27K |
| Net Cash from Investing | -$622K | -$1.48M | -$1.31M | $51.97M | -$60.13M | -$1.74M | $9.26M |
| Financing Activities | |||||||
| Debt Repaid | $3.12M | -$14.78M | -$10M | -$4.48M | -$4.97M | - | -$7M |
| Common Stock Issuance | $84.54M | $81.75M | $54.99M | $0 | $75.83M | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $234K | $1.01M | $471K | $511K | -$128K | $64K | $1.25M |
| Net Cash from Financing | $81.66M | $97.54M | $65.47M | $4.99M | $162.01M | $48.97M | $15.74M |
| Forex Effect | -$454K | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$20.66M | -$666K | -$8.91M | -$15.02M | $54.6M | $23.96M | $12.69M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$101.23M | -$96.72M | -$73.06M | -$71.98M | -$47.28M | -$23.27M | -$12.31M |
| Capital Expenditure | -$622K | -$1.52M | -$1.32M | -$3.03M | -$5.46M | -$1.74M | -$1.25M |
| Free Cash Flow | -$101.86M | -$98.24M | -$74.38M | -$75.01M | -$52.74M | -$25.01M | -$13.56M |
| Cash at Beginning | $69.75M | $70.42M | $79.33M | $94.35M | $39.75M | $15.79M | $3.1M |
| Cash at End | $49.1M | $69.75M | $70.42M | $79.33M | $94.35M | $39.75M | $15.79M |